While many small-cap stocks have been on an uptrend lately; and most of the times, the stocks move based on significant developments and investors’ view of the developments and future impacts. Small-cap sector is thus prone to many risks as opposed to blue-chip and mid-cap, and below are two stocks of the category that were discussed lately for slipping on ASX.
LiveTiles Limited (ASX: LVT) is an information technology company and for $20 million worth of shares in software company LiveTiles, Stockbrokers Citi and Blue Ocean Equities are seeking buyers. At a 21.9 percent discount the deal was priced. In the last 12 months, LiveTiles has aligned itself to Microsoft’s ‘AI-first’ vision and becomes a key strategic partner in the data and AI space. LiveTiles is again a major sponsor in the award which comes ahead of Microsoft’s flagship partner conference. Held at the Mandalay Bay Convention Center in Las Vegas from July 15-19 Microsoft Inspire is attended by over 21,000 people from around the world. The company traded at a market price of $0.670 on August 09, 2018 as it slipped owing to the share placement and purchase plan update, and has seen a performance change of 219% over the past 12 months.
OncoSil Medical Limited (ASX:OSL) is a health care medical device company and focusing on oncology. For pancreatic cancer, the company is commercializing a break through implantation radiation treatment; and is targeting more than $2bn market opportunity to improve standard of care. Manufacturing and logistics have been optimized for supply of commercial quantities. U.S. FDA-approved IDE is in place and safety run-in is underway; then CE Marking is expected in near-term. Its incorporation date was 2005 and is based in Berry Street, North Sydney, Australia.
The company was trading at a market price of $0.180 as at market open on August 10, 2018, and has seen a performance change of 83.67% over the past 12 months. The group has fallen about 12% in last five days. It has commercialized a breakthrough implantation for pancreatic cancer. To improve standard for care, the company is targeting more than 2 billion market opportunity. The enterprise value of the company is A $ 122.1 million and the market capitalization stands at $112.35 million. The company claims to have a first in class technology, and highly experienced management team. The Company also received an additional cash refund of $0.6 million in January 2018 following lodgment of the 2016/17 amended tax return.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.